← Back to Search

mPal Strategy for Palliative Care in Lung Cancer

N/A

Recruiting

Led By Laurie McLouth, PhD

Research Sponsored by Laurie McLouth

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

ECOG performance status 0-3/Karnofsky 40-100

New or recurrent AJCC stage IIIb-IV non-small cell lung cancer or extensive stage small cell lung cancer

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 6 months

Awards & highlights

Study Summary

This trial will test a new way to improve palliative care for lung cancer patients receiving treatment.

Who is the study for?

This trial is for adults with advanced stage lung cancer (non-small cell or small cell) who are already a few weeks into their cancer treatment. They should be able to perform daily activities with varying degrees of assistance and must speak and read English. Those with unstable brain conditions, severe cognitive issues, or existing palliative care cannot participate.Check my eligibility

What is being tested?

'mPal' is being tested in this study. It's a strategy designed to improve the use of palliative care among patients undergoing treatment for advanced lung cancer. The focus is on seeing if 'mPal' works well and if people find it acceptable.See study design

What are the potential side effects?

Since 'mPal' is not a drug but a strategy to implement palliative care, traditional medication side effects are not applicable here. However, there may be emotional or psychological impacts from participating in an enhanced palliative care program.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I can care for myself but may not be able to do active work.

Select...

My lung cancer is at an advanced stage.

Select...

I have been undergoing cancer treatment for at least three weeks.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 6 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 6 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 6 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Feasibility of enrollment: Proportion of eligible and approached patients who agree to participate

Secondary outcome measures

Acceptability of intervention

Change in palliative care attitudes

Change in palliative care knowledge

+3 more

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: mPal interventionExperimental Treatment1 Intervention

Participants in this group will receive the mPal intervention. mPal's patient content includes a multi-component web-based tool with the following: (1) a brief educational video that seeks to educate patients about palliative care; (2) and assessment of palliative care knowledge; (3) assessment of palliative care needs; and (4) an assessment of whether patients would like to meet with palliative care or discuss palliative care and their palliative care needs with their oncology provider. mPal's provider content (not randomized) will include education. System-level modifications will also be made to the electronic health record to facilitate palliative care discussions and referrals.

Group II: Standard of careActive Control1 Intervention

Participants in this group will receive standard of care (applies to patients only).

0 / 3Eligibility criteria met

Find a Location

Who is running the clinical trial?

Laurie McLouthLead Sponsor

3 Previous Clinical Trials

327 Total Patients Enrolled

National Center for Advancing Translational Sciences (NCATS)NIH

321 Previous Clinical Trials

401,669 Total Patients Enrolled

Laurie McLouth, PhDPrincipal InvestigatorUniversity of Kentucky

2 Previous Clinical Trials

287 Total Patients Enrolled

Media Library

mPal Clinical Trial Eligibility Overview. Trial Name: NCT05270395 — N/A

mPal 2023 Treatment Timeline for Medical Study. Trial Name: NCT05270395 — N/A

Lung Cancer Clinical Trial 2023: mPal Highlights & Side Effects. Trial Name: NCT05270395 — N/A

Lung Cancer Research Study Groups: mPal intervention, Standard of care

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is enrollment currently ongoing for this clinical trial?

"This clinical study, which was initially posted to clinicaltrials.gov on July 28th 2022, is still in need of participants and its information was most recently refreshed on the 29th of July."

Answered by AI

What are the criteria for a person to partake in this research effort?

"60 participants, aged 18 to 100, with a diagnosis of lung cancer are being sought. They must have either AJCC stage IIIb-IV non-small cell or extensive stage small cell carcinoma and possess an ECOG performance status 0-3/Karnofsky 40-100 score as well as be no less than three weeks into oncologic treatment (chemotherapy, immunotherapy, chemoimmunotherapy)."

Answered by AI

To what extent is this medical study being populated with volunteers?

"Affirmative. Clinicaltrials.gov verifies that the clinical trial, initially posted on July 28th 2022, is currently recruiting individuals to participate in the study. Here it is aiming to recruit 60 participants from a single medical centre."

Answered by AI